3.98  0.17 (4.46%)		12-15 15:59
Open: 3.755 High: 4.04 Volume: 270,225		Pre. Close: 3.81 Low: 3.755 Market Cap: 38(M)

Short term
Mid term
Targets	6-month :	4.89	1-year :	5.71
Resists	First :	4.19	Second :	4.89
Pivot price	3.81
Supports	First :	3.45	Second :	3
MAs	MA(5) :	3.76	MA(20) :	3.81
	MA(100) :	2.71	MA(250) :	0
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	54.8	D(3) :	47.6
RSI	RSI(14): 59.7
52-week	High :	6.59	Low :	1

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SABS ] has closed below upper band by 23.4%. Bollinger Bands are 19.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	4.04 - 4.06	4.06 - 4.08
Low:	3.71 - 3.73	3.73 - 3.75
Close:	3.95 - 3.98	3.98 - 4.01

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

Mon, 08 Dec 2025
SAB Biotherapeutics to Present Data on SAB-142 for Type 1 Diabetes at ATTD-Asia Conference 2025 - Quiver Quantitative

Thu, 04 Dec 2025
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Sat, 22 Nov 2025
We Think SAB Biotherapeutics (NASDAQ:SABS) Can Afford To Drive Business Growth - simplywall.st

Mon, 17 Nov 2025
Chardan Capital Maintains SAB Biotherapeutics (SABS) Buy Recommendation - Nasdaq

Thu, 13 Nov 2025
SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights - Investing News Network

Tue, 04 Nov 2025
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 - Investing News Network

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	-20 (M)
Shares Float	0 (M)
Held by Insiders	4.761e+007 (%)
Held by Institutions	2.259e+007 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	-3.033e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-1.56
Profit Margin	16 %
Operating Margin	338.3 %
Return on Assets (ttm)	-37 %
Return on Equity (ttm)	657.1 %
Qtrly Rev. Growth	18.5 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-4.009e+007 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	-2.56
Price to Sales	0
Price to Cash Flow	0

Dividend	702330
Forward Dividend	696990
Dividend Yield	17646500%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.